ATXN1 Antibody (S776) Blocking Peptide
€293.00
In stock
SKU
AC-BP2808a
Background:
The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the `pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted to successive generations. The function of the ataxins is not known.
Other Names: Ataxin-1, Spinocerebellar ataxia type 1 protein, ATXN1, ATX1, SCA1
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP2808a was selected from the S776 region of human ATXN1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Type: Synthetic peptide
Primary Accession: P54253
Gene ID: 6310
Gene Name: ATXN1
Format: Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.
Bio References:
Hong,S., Biochem. Biophys. Res. Commun. 371 (2), 256-260 (2008)Lim,J., Nature 452 (7188), 713-718 (2008)Krol,H.A., PLoS ONE 3 (1), E1503 (2008)
The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the `pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted to successive generations. The function of the ataxins is not known.
Other Names: Ataxin-1, Spinocerebellar ataxia type 1 protein, ATXN1, ATX1, SCA1
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP2808a was selected from the S776 region of human ATXN1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Type: Synthetic peptide
Primary Accession: P54253
Gene ID: 6310
Gene Name: ATXN1
Format: Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.
Bio References:
Hong,S., Biochem. Biophys. Res. Commun. 371 (2), 256-260 (2008)Lim,J., Nature 452 (7188), 713-718 (2008)Krol,H.A., PLoS ONE 3 (1), E1503 (2008)
| Is Featured? | No |
|---|
Write Your Own Review